Galmed Announces ARRIVE Study Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Alibaba (BABA) PT Lowered to $165 at Bernstein SocGen Group
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
H.C. Wainwright Remains Bullish on Galmed Pharma (GLMD) Followng Sell Off
February 15, 2018 8:58 AM ESTH.C. Wainwright reiterated a Buy rating and $24.00 price target on Galmed Pharmaceuticals (NASDAQ: GLMD) following the company's announcement that the ARRIVE study did not meet its primary endpoint of improvement in liver fat at 12 weeks. Shares closed at $5.45, down -42.4%, after recovering somewhat... More
H.C. Wainwright Remains Bullish on Galmed Pharma (GLMD) Followng Sell Off
February 15, 2018 8:58 AM ESTH.C. Wainwright reiterated a Buy rating and $24.00 price target on Galmed Pharmaceuticals (NASDAQ: GLMD) following the company's announcement that the ARRIVE study did not meet its primary endpoint of improvement in liver fat at 12 weeks. Shares closed at $5.45, down -42.4%, after recovering somewhat... More
